Dominik Kirchhofer

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.

Journal: Journal of experimental & clinical cancer research : CR

Published: January 28, 2026

Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma.

Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma.

Journal: Antioxidants (Basel, Switzerland)

Published: November 07, 2025

Tumor-suppressive role of miR-216b impacts cell cycle regulation in high-grade glioma.

Tumor-suppressive role of miR-216b impacts cell cycle regulation in high-grade glioma.

Journal: Acta neuropathologica communications

Published: September 29, 2025

Small Particles, Big Problems: Polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cells.

Small Particles, Big Problems: Polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cells.

Journal: Journal of hazardous materials

Published: March 07, 2025

Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma.

Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma.

Journal: British journal of cancer

Published: March 04, 2025

Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome.

Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome.

Journal: Redox biology

Published: December 16, 2024

A new fluorescent oxaliplatin(iv) complex with EGFR-inhibiting properties for the treatment of drug-resistant cancer cells.

A new fluorescent oxaliplatin(iv) complex with EGFR-inhibiting properties for the treatment of drug-resistant cancer cells.

Journal: Inorganic chemistry frontiers

Published: December 03, 2024

Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.

Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.

Journal: Neuro-oncology

Published: November 18, 2024

Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation.

Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation.

Journal: Cancer & metabolism

Published: July 22, 2024

The tyrosine kinase inhibitor Nintedanib induces lysosomal dysfunctionality: Role of protonation-dependent crystallization processes.

The tyrosine kinase inhibitor Nintedanib induces lysosomal dysfunctionality: Role of protonation-dependent crystallization processes.

Journal: Chemico-biological interactions

Published: July 16, 2024

EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer.

EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer.

Journal: EMBO molecular medicine

Published: May 16, 2024

POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells.

POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells.

Journal: Cell reports

Published: March 18, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026